Document is current
Any future updates will be listed below
-
Authors
Fujii, Fumiaki
Onozawa, Masahiro https://orcid.org/0000-0001-9267-2864
Yoshida, Shota
Miyashita, Naoki
Hidaka, Daisuke
Ogasawara, Reiki
Takahata, Mutsumi
Hashiguchi, Junichi
Yokoyama, Shota
Chiba, Masahiro
Saga, Tomoyuki
Shimizu, Taku
Kasahara, Ikumi
Shigematsu, Akio
Fujimoto, Katsuya
Iyama, Satoshi
Igarashi, Tetsuyuki
Ito, Shinichi
Haseyama, Yoshihito
Kosugi-Kanaya, Mizuha
Kondo, Takeshi
Teshima, Takanori
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 7 November 2025
Revised: 4 March 2026
Accepted: 5 March 2026
First Online: 19 March 2026
Declarations
:
: MO has received honoraria from AbbVie, Nippon Shinyaku, Otsuka Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Novartis, Astellas, and research funding from AbbVie. KF has received research funding from Bristol Myers Squibb, Parexel International, Insight Biosciences Japan, Janssen Pharmaceutical, and Mitsubishi Tanabe Pharma. SI has received honoraria from Alexion Pharmaceuticals, Astellas, Nippon Shinyaku, Novartis, Otsuka, Sanofi, SymBio Pharmaceuticals, Asahikasei-pharma, Kyowa Kirin, and Chugai pharmaceutical; received research funding from MSD, Otsuka, JCR pharma, Chugai pharmaceutical, Kyowa Kirin, Novartis. MKK is an employee of AbbVie. TK has received honoraria from Bristol Myers Squibb, Otsuka Pharmaceutical, Novartis, and Pfizer. TT has received honoraria from Astellas, Kyowa Kirin, Novartis Pharma, Bristol Myers Squibb, AstraZeneca, AbbVie, Gilead Sciences, Nippon Shinyaku, Janssen Pharmaceutical; received research funding from LUCA Science, Priothera, PharmaEssentia Japan, AbbVie, IQVIA Services Japan, Kyowa Kirin, CMIC, Chugai Pharmaceutical, Novartis, Janssen, CSL Behring, Gilead Sciences; received educational or unrestricted grants from Kyowa Kirin, Sumitomo Pharma, and Chugai Pharmaceutical. The other authors declare no conflicts of interest. AbbVie funded this study.
